Trial Profile
A Pilot Study of Mitoxantrone in Combination With Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) With Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Jan 2023
Price :
$35
*
At a glance
- Drugs Clofarabine (Primary) ; Mitoxantrone (Primary) ; Cytarabine; Dexrazoxane; Rituximab
- Indications Acute myeloid leukaemia; Burkitt's lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Acronyms MITCL
- 13 Dec 2022 Results assessing the safety, overall response rate and long term EFS/OS in a Phase I/II trial of clofarabine in combination with mitoxantrone as reinduction therapy for relapsed or refractory pediatric acute leukemia, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 24 Oct 2022 Status changed from active, no longer recruiting to completed.
- 29 Oct 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.